The unreported harms of the Swiss psychedelic program

Swiss psychedelic-assisted therapy can produce serious, sometimes life-threatening harms that may go unreported under the countrys limited medical use framework. A case study describes a patient given MDMA for C-PTSD under Switzerlands compassionate access program, without clear warnings about prolonged post-session difficulties. Months later the patient reports extreme instability, derealization and depersonalization, tinnitus, a brief psychotic episode with voices urging self-harm, suicidality, and repeated emergency psychiatric visits. The authors claim this case was not formally reported to the Swiss Federal Office of Public Health (FOPH). The piece contrasts Swiss reporting categories and delays in adverse event capture with broader regulatory gaps between the FOPH authorization process and Swissmedics pharmacovigilance systems. It outlines how serious adverse events are variably defined and how physicians reporting is voluntary, with long-term follow-up and centralized registries lacking. It also points to psilocybin-related deaths assessed by physicians as having no causal link, and argues that system-level underreporting limits safety conclusions.